Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Claire Long

- PMLiVE

Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline

The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m

- PMLiVE

Vibrant Therapeutics appoints Han Lee as co-CEO

Lee previously held senior roles at ImmPACT Bio, Neogene Therapeutics and AstraZeneca

- PMLiVE

From patients to consumers: why pharma communications must rethink the rules of engagement

By Sarah Greenidge

- PMLiVE

How will AI change field training?

Learn how a next-generation approach to field training – powered by GenAI and avatar simulations and enabled through Intelligent Commercialization™ – can transform field force effectiveness by delivering scalable, always-on,...

Inizio

- PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Around 64 million people worldwide live with psoriasis

- PMLiVE

NanoSyrinx appoints Thomas J Farrell as CEO

Farrell was previously founder and CEO of two NASDAQ-listed companies

- PMLiVE

AbbVie reaches agreement for affordable prescription drugs with US government

The pharma company has also pledged a $100bn investment in US infrastructure over the next decade

- PMLiVE

VML Health appoints Nadine Leonard as Global Chief Solutions & Innovation Officer

Leonard was previously Therapeutic Area Lead for Pfizer’s oncology branch

- PMLiVE

Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity

Obesity affects approximately 15 million people in the UK

- PMLiVE

Enhanced Genomics appoints Katerina Leftheris to Board of Directors

Leftheris has held senior scientific roles at Bristol Myers Squibb and Celgene

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Johnson & Johnson’s Rybrevant shows positive effects in difficult-to-treat colorectal cancer

Colorectal cancer accounts for around 10% of all cancer cases globally, with an increase in diagnoses in younger people

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links